Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Update

Assembly Biosciences, Inc. (NASDAQ:ASMB) was the target of a large decrease in short interest in April. As of April 15th, there was short interest totalling 30,600 shares, a decrease of 28.2% from the March 31st total of 42,600 shares. Approximately 0.8% of the shares of the stock are short sold. Based on an average daily volume of 27,700 shares, the short-interest ratio is currently 1.1 days.

Assembly Biosciences Price Performance

Shares of NASDAQ:ASMB traded down $0.71 on Friday, hitting $12.65. The company’s stock had a trading volume of 29,550 shares, compared to its average volume of 17,185. The company has a 50-day simple moving average of $13.07 and a 200 day simple moving average of $11.07. Assembly Biosciences has a 1 year low of $7.69 and a 1 year high of $20.04. The company has a market capitalization of $69.36 million, a PE ratio of -0.74 and a beta of 0.57.

Institutional Trading of Assembly Biosciences

An institutional investor recently bought a new position in Assembly Biosciences stock. Acuitas Investments LLC acquired a new stake in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 265,585 shares of the biopharmaceutical company’s stock, valued at approximately $218,000. Acuitas Investments LLC owned about 0.40% of Assembly Biosciences at the end of the most recent quarter. Institutional investors and hedge funds own 19.92% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. StockNews.com raised Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Friday, April 5th. HC Wainwright reaffirmed a “neutral” rating on shares of Assembly Biosciences in a report on Monday, April 1st.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.